Long-term efficacy of Interferon-alpha in chronic inflammatory demyelinating polyneuropathy

Pavesi, Giovanni; Cattaneo, Luigi; Marbini, A; Gemignani, F; Mancia, D

doi:10.1007/s00415-002-0693-5

Cited by 31 publications

(12 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In two patients with HCV infection and CIDP, IFN‐α was thought to be responsible for the neuropathy,25, 27 whereas in two others it appeared to have a beneficial effect 7, 19. To complicate the matter, IFN‐α was also proposed as a treatment for refractory CIDP 17, 31. In the patient reported in the present study, the neuropathy relapsed clinically and electrophysiologically during IFN‐α treatment and viral eradication, but responded again to steroids, which were continued for 68 weeks without worsening of hepatitis or the reappearance of virus in the blood.…”

Section: Discussionmentioning

confidence: 99%

Lewis–Sumner syndrome in hepatitis C virus infection: A possible pathogenetic association with therapeutic problems

Caporale

Capasso

Ragno³

et al. 2006

Muscle and Nerve

View full text Add to dashboard Cite

A patient with chronic hepatitis from hepatitis C virus (HCV) infection developed Lewis-Sumner syndrome (LSS). The neuropathy worsened after intravenous immunoglobulins, remitted after intravenous methylprednisolone, relapsed during interferon-alpha, but responded again to steroids continued for 68 weeks with clinical remission and without worsening of hepatitis. We are not aware of other reports of HCV infection and LSS. This association may be coincidental or related to a virus-triggered immune-mediated process. Although the coexistence of a dysimmune neuropathy with hepatitis makes problematic the choice of treatment, we emphasize that the patient's condition during treatment with steroids and the 46 following weeks without therapy has been excellent.

show abstract

Section: Discussionmentioning

confidence: 99%

Lewis–Sumner syndrome in hepatitis C virus infection: A possible pathogenetic association with therapeutic problems

Caporale

Capasso

Ragno³

et al. 2006

Muscle and Nerve

View full text Add to dashboard Cite

show abstract

“…3 This explains our therapeutic decision. Over the last few years, several authors had noticed that interferon-␣ could be an alternative in the treatment of demyelinating neuropathies either associated with or not HCV infections, 8,9 but to date, the mechanism of improvement has remained unspecified. Conversely, CIDP has also been reported as a neurologic complication of interferon-alpha in HCV patients, but it seems that in such cases, viral eradication has not been obtained.…”

Section: Discussionmentioning

confidence: 99%

Improvement of a CIDP associated with hepatitis C virus infection using antiviral therapy

Corcia¹,

Barbereau²,

Guennoc³

et al. 2004

Neurology

View full text Add to dashboard Cite

A 57-year-old man with chronic inflammatory demyelinating polyneuropathy associated with hepatitis C virus infection was treated successfully with the combination of peginterferon-alpha-2b and ribavirin. Viral eradication was confirmed during the 4th week of treatment and was followed 3 weeks later by neurologic improvement. The patient resumed normal activity 1 year after the therapy was completed.

show abstract

“…Common side effects include injection site reactions, flu-like symptoms, hepatotoxicity, and possible psychiatric reactions such as depression. As with the other agents, many small case studies have shown clinical improvement in patients with CIDP treated with either beta interferon [90][91][92][93] or alpha interferon [94,95]. However, a small, randomized controlled study failed to prove a beneficial effect of interferon -1a in CIDP [78].…”

Section: Interferonmentioning

confidence: 97%

Chronic inflammatory demyelinating polyneuropathies: Current treatment strategies

Toothaker¹,

Brannagan

2007

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

Chronic inflammatory demyelinating polyradiculopathy (CIDP), considered an immune-mediated disease, is likely under-recognized and under-treated due to its heterogeneous presentation and the limitations of clinical, serologic, and electrophysiologic diagnostic criteria. Despite these limitations, early diagnosis and treatment is important in preventing irreversible axonal loss and improving functional recovery. Primary treatment modalities include intravenous immunoglobulin and plasmapheresis, for which there is randomized, double-blind, placebo-controlled evidence. In addition, despite less definitive published evidence of efficacy, corticosteroids are considered standard therapies because of their long history of use. Studies have failed to demonstrate a difference in efficacy among these three treatments; consequently, the choice is usually based on availability and side-effect profile. A number of chemotherapeutic and immunosuppressive agents have also shown to be effective in treating CIDP but significant evidence is lacking; therefore, these agents are primarily used in conjunction with other modalities. Regardless of the treatment choice, long-term therapy is required to maintain a response and prevent relapse.

show abstract

Long-term efficacy of Interferon-alpha in chronic inflammatory demyelinating polyneuropathy

Cited by 31 publications

References 17 publications

Lewis–Sumner syndrome in hepatitis C virus infection: A possible pathogenetic association with therapeutic problems

Lewis–Sumner syndrome in hepatitis C virus infection: A possible pathogenetic association with therapeutic problems

Improvement of a CIDP associated with hepatitis C virus infection using antiviral therapy

Chronic inflammatory demyelinating polyneuropathies: Current treatment strategies

Contact Info

Product

Resources

About